GSK completed the acquisition of BELLUS Health for $2bn.

GSK, a global healthcare company, completed the acquisition of BELLUS Health, a biopharmaceutical company, for $2bn. “This acquisition recognises the value of our highly selective P2X3 antagonist camlipixant and validates the hard work and dedication of all the BELLUS employees in advancing camlipixant to date. As a leader in respiratory research for over five decades, GSK shares our commitment to bettering the lives of individuals suffering from a persistent cough and is the ideal Company to rapidly bring camlipixant to the millions suffering from refractory chronic cough around the world,” Roberto Bellini, BELLUS CEO.